Clinical Study

Initial Dose of Three Monthly Intravitreal Injections versus PRN Intravitreal Injections of Bevacizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion

Figure 1

Mean best-corrected visual acuity (BCVA) change from baseline to 12 months. There was no significant difference in BCVA changes between the PRN group and the 3 monthly initial dose group at all postoperative visits. Error bars denote upper or lower bound of 95% confidence intervals. Statistical analyses were performed using Student’s -tests. The numbers on the right side of the arrow indicate the number of patients who were retreated with intravitreal bevacizumab injections at that time.
209735.fig.001